Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive (ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This biomarker has been extensively studied and is easily assayed by histopathologists but it is not currently accepted...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer US
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332349/ |